Perimeter Medical Imaging AI’s B-Series OCT Achieves Pivotal Trial Success

The latest update is out from Perimeter Medical Imaging AI ( (TSE:PINK) ).

Perimeter Medical Imaging AI announced successful results from a pivotal trial of its B-Series OCT with ImgAssist AI 2.0, presented at the American Society of Breast Surgeons 2025 meeting. The trial demonstrated a statistically significant reduction in residual cancer during surgery, meeting its primary endpoint and showcasing the device’s potential to improve surgical outcomes by reducing re-excisions and enhancing intraoperative decision-making. The company has submitted a Premarket Approval application to the FDA, marking a significant milestone in its regulatory journey.

Spark’s Take on TSE:PINK Stock

According to Spark, TipRanks’ AI Analyst, TSE:PINK is a Neutral.

Perimeter Medical Imaging AI is positioned in a growth phase with strong revenue increases and promising clinical advancements towards FDA approval. However, persistent net losses, cash flow constraints, and bearish technical indicators pose significant challenges. The valuation remains unattractive, but recent strategic corporate events offer potential for future expansion.

To see Spark’s full report on TSE:PINK stock, click here.

More about Perimeter Medical Imaging AI

Perimeter Medical Imaging AI, Inc. is a commercial-stage medical technology company focused on developing advanced imaging tools for intraoperative margin assessment, particularly in breast cancer surgeries. Their primary product, the B-Series OCT with ImgAssist AI 2.0, aims to enhance real-time decision-making during breast-conserving surgeries by providing surgeons with improved imaging capabilities.

YTD Price Performance: -13.33%

Average Trading Volume: 62,532

Technical Sentiment Signal: Strong Buy

Current Market Cap: C$34.52M

Find detailed analytics on PINK stock on TipRanks’ Stock Analysis page.